Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein

Molecular Pharmacology

Volumn 61, Issue 5, 2002, Pages 964-973

  Ekins, Sean ^a   Kim, Richard B ^b   Leake, Brenda F ^c   Dantzig, Anne H ^c   Schuetz, Erin G ^b,c   Lan, Lu Bin ^c   Yasuda, Kazuto ^a,b   Shepard, Robert L ^a   Winter, Mark A ^a,b   Schuetz, John D ^c   Wikel, James H ^b,c   Wrighton, Steven A ^c  

^a ELI LILLY AND COMPANY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; CAFFEINE; CALCEIN; CHLORZOXAZONE; DEBRISOQUINE; DIGOXIN; ERGOT ALKALOID; FENTANYL; FEXOFENADINE; FLUOXETINE; GLYCOPROTEIN P INHIBITOR; INDINAVIR; IVERMECTIN; KETOCONAZOLE; LOPERAMIDE; MEPHENYTOIN; MIBEFRADIL; MIDAZOLAM; MORPHINE; NELFINAVIR; PROCAINAMIDE; PROTEIN INHIBITOR; QUINIDINE; SAQUINAVIR; SUFENTANIL; TAMOXIFEN; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG STRUCTURE; DRUG TRANSPORT; HYDROGEN BOND; HYDROPHOBICITY; IC 50; IN VITRO STUDY; KIDNEY EPITHELIUM; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SWINE; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CACO-2 CELLS; ERGONOVINE; FLUOXETINE; HUMANS; MODELS, MOLECULAR; OXYTOCICS; P-GLYCOPROTEIN; PROTEIN CONFORMATION; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TRANSFECTION; VINBLASTINE;

EID: 18344390872     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.5.964     Document Type: Article

References (37)

1. Co-operative, competitive and noncompetitive interactions between modulators of P-glycoprotein
2. Classification of multidrug-resistance reversal agents using structure-based descriptors and linear discriminant analysis
3. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity
4. Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance
5. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
6. Identification of the cyclosporin-binding site in P-glycoprotein
7. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
8. The importance of a nitrogen atom in modulators of multidrug resistance
9. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of inhibitors for CYP3A4
10. Predicting drug-drug interactions in silica using pharmacophores: A paradigm for the next millennium
11. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
12. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
13. Quantitative structure-activity relationship of multidrug resistance reversal agents
14. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing
15. + gradient-stimulated uptake
16. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites
17. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parameterization and PLS statistics
18. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study
19. QSAR and molecular modelling of catamphiphilic drugs able to modulate multidrug resistance in tumors
20. A comparitive molecular field analysis of propafenone-type modulators of cancer multidrug resistance
21. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance
22. Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance
23. Reversal of multidrug resistance by phenothiazines and structurally related compounds
24. Studies on propafenone-type modulators of multidrug resistance VIII: Synthesis and pharmacological activity of indanon analogues
25. P-glycoprotein substrates and antagonists cluster into two distinct groups
26. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A
27. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements
28. Extracellular matrix regulation of multidrug resistance in primary monolayer cultures of adult rat hepatocytes
29. How does P-glycoprotein recognize its substrates?
30. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities
31. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein
32. Measurement of protein using bicinchoninic acid
33. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay
34. A combined Hansch/free Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance
35. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
36. Interaction between P-glycoprotein and opioids
37. SMILES 1. Introduction and encoding rules